VivoSeq
Oncology

Relapsed or Refractory Multiple Myeloma

13

Pipeline Programs↗

6

Active Trials↗

8

Companies Involved↗

Relapsed or Refractory Multiple Myeloma is an emerging landscape with 13 programs across 8 companies. The most active players are Roche, Pfizer, Johnson & Johnson. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

11/100

Mech. Concentration

17/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1Pfizer logo

Pfizer

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

3 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 3Moderna logo

Moderna

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

12programs
Small molecule650%
Monoclonal antibody433%
Protein / enzyme18%
RNA therapy18%

Modality classified for 92% of 13 pipeline programs.

Analysis

Trial Status

6

clinical trials

Recruiting4 · 67%
Active, not recruiting1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Recruiting·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT05519085·810 enrolled
Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05652335·180 enrolled
An Open-Label, Multicenter, Phase Ib Trial Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Patients With Relapsed or Refractory Multiple Myeloma
Recruiting·Roche logoRoche·Phase 1·NCT05927571·120 enrolled
A Phase 1/2, Open-label, Multicenter Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting·Moderna logoModerna·Preclinical·NCT07116616·166 enrolled
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-87562761 in Relapsed/Refractory Multiple Myeloma
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06604715·17 enrolled
A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Efficacy of AZD4045, an Allogeneic Chimeric Antigen Receptor-T Cell (CAR-T) Therapy Targeting B Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Not yet recruiting·AstraZeneca logoAstraZeneca·Preclinical·NCT07681596·101 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)